Jupiter Neurosciences lands exclusive U.S. rights to ALA-002

Jupiter Neurosciences signed a definitive agreement with PharmAla Biotech Holdings for perpetual exclusive U.S. rights to ALA-002, a patented MDMA-based drug candidate with FDA Novel Chemical Entity designation. The deal could be worth up to $100 million and gives Jupiter a second clinical-stage CNS asset alongside its Parkinson’s program.

Why it matters: - The agreement turns Jupiter Neurosciences from a single-program company into a dual clinical-stage central nervous system developer. - ALA-002 adds a second asset to Jupiter’s pipeline and gives the company perpetual exclusive U.S. rights to a drug candidate with FDA Novel Chemical Entity status. - The deal could also give Jupiter a long-term commercial foothold in the U.S. psychedelic therapeutics market, which the company cites as expanding rapidly.

What happened: - Jupiter Neurosciences entered a definitive license agreement with PharmAla Biotech Holdings for exclusive U.S. rights to ALA-002. - The company announced the transaction on July 22, 2026. - The agreement covers perpetual exclusive rights in the United States. - Jupiter said the deal has potential value of up to $100 million, including milestone payments and excluding ongoing royalties.

The details: - Jupiter will make a $3.3 million upfront payment, split between $1.5 million in cash and $1.8 million in JUNS common stock subject to a 120-day lock-up. - Jupiter will owe a $3.3 million development milestone when ALA-002 reaches Phase 3 first patient in. - Jupiter will owe a $20 million regulatory milestone upon U.S. NDA approval. - Commercial milestones are set at $10 million, $30 million and $33.3 million when cumulative U.S. net sales reach $333 million, $1 billion and $2 billion. - Jupiter will owe a 3% royalty on net sales after the third commercialization milestone. - ALA-002 is a patented, non-racemic MDMA formulation. - The FDA has granted ALA-002 Novel Chemical Entity designation, which provides enhanced regulatory protection and a five-year data exclusivity period upon approval. - Jupiter said ALA-002 is designed to improve cardiovascular safety and reduce abuse liability versus racemic MDMA while preserving the therapeutic properties used in MDMA-assisted psychotherapy. - PharmAla’s MDMA supply is active in U.S. government-sponsored VA and DHA clinical trials. - PharmAla will continue manufacturing ALA-002 drug product for Jupiter under commercial terms to be negotiated. - The company said that should accelerate Jupiter’s development timelines. - Jupiter’s current lead program is JOTROL™, a proprietary enhanced-bioavailability resveratrol formulation in a Phase IIa Parkinson’s disease trial. - Jupiter also commercializes Nugevia™, a consumer longevity supplement.

Between the lines: - The transaction gives Jupiter a second independent development path while keeping its Parkinson’s program in play. - Management is betting that FDA regulatory momentum around psychedelic medicines could improve the path for ALA-002. - The agreement also adds complexity: the headline value depends on development progress, regulatory approval and commercial performance. - Forward-looking claims in the release depend on clinical results, regulatory review, financing and other risks.

What’s next: - Jupiter will work toward clinical execution across both its Parkinson’s program and ALA-002. - PharmAla will continue supplying ALA-002 drug product as the companies negotiate commercial manufacturing terms. - Jupiter said the next 12 months will be transformative as it advances strategy, board expertise and execution in psychedelic medicine. - Future value creation hinges on clinical milestones, U.S. regulatory progress and eventual commercialization.

The bottom line: - Jupiter is making a bigger bet on CNS drugs by adding a regulated psychedelic asset with meaningful upside and significant execution risk.

More information is available in the company's announcement.